Aytu BioPharma, Inc. and Lannett Company, Inc. have mutually agreed to terminate their exclusive license agreement for the ADHD medication Metadate CD®, effective June 23, 2026. The original agreement was signed on May 11, 2022.
Key Details
- Agreement Terminated: The exclusive license agreement between Aytu BioPharma and Lannett Company, originally established on May 11, 2022.
- Effective Date: The termination was effective as of June 23, 2026.
- Post-Termination Terms: Aytu may continue to sell its existing inventory of Metadate CD® and is required to continue paying royalties on these sales until the inventory is depleted.
- Financial Context: Net revenue for Metadate CD® reported by Aytu for the quarter ended March 31, 2026, was $49,000.